1. Home
  2. ELDN vs NPCT Comparison

ELDN vs NPCT Comparison

Compare ELDN & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

SELL

Current Price

$2.35

Market Cap

291.8M

Sector

Health Care

ML Signal

SELL

Logo Nuveen Core Plus Impact Fund of Beneficial Interest

NPCT

Nuveen Core Plus Impact Fund of Beneficial Interest

SELL

Current Price

$9.00

Market Cap

286.7M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ELDN
NPCT
Founded
2004
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
291.8M
286.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ELDN
NPCT
Price
$2.35
$9.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $9.00
N/A
AVG Volume (30 Days)
★ 753.8K
96.5K
Earning Date
11-13-2026
01-01-0001
Dividend Yield
N/A
★ 9.82%
EPS Growth
★ 30.67
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$8.89
52 Week High
$4.60
$10.82

Technical Indicators

Market Signals
Indicator
ELDN
NPCT
Relative Strength Index (RSI) 29.21 27.20
Support Level $1.96 N/A
Resistance Level $3.14 $9.90
Average True Range (ATR) 0.11 0.14
MACD 0.01 -0.01
Stochastic Oscillator 10.13 12.96

Price Performance

Historical Comparison
ELDN
NPCT

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income.

Share on Social Networks: